INDIA MARKET LENS
Markets◆ Mixed

Strand eyes US, Southeast Asia mkts for blood-based cancer screening test

· BS Companies

Reliance-backed genomics company is pursuing US FDA approval for CancerSpot and aims to cut its price in India to below ₹10,000 over the next two to three years.

All Markets news →